Novel nanotherapeutics
Ended Awarded Last action
- Contract number
- HT942524F0269
- Awardee
-
Eitr Biologics, Inc. UEI HX49LZLY32G5
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,864,156
Award facts
- Opportunity
-
- HT942523R0061 Solicitation number
- Contract value 100% obligated
-
- $1,864,156.31 Current, with exercised options
- $1,864,756.31 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $424,187 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $358,340 | |
| Original award | $1,081,629 |
About this award
The Defense Health Agency awarded a $1.86M firm-fixed-price delivery order to Eitr Biologics, Inc. on September 20, 2024, for novel nanotherapeutics development. The San Diego-based biotechnology company will perform work through December 31, 2025. This delivery order is issued under Eitr Biologics' existing Indefinite Delivery Vehicle (IDV) contract with the Defense Health Agency, valued at $4.39M through August 2028, which focuses specifically on developing novel nanotherapeutics to combat biological threats, particularly pneumonic plague caused by Yersinia pestis. No set-aside designation was used for this award.
Eitr Biologics specializes in advanced medical countermeasures, antibody-based therapeutic platforms, and nanotherapeutic solutions targeting viral and bacterial infections. The company has established a track record with the Defense Health Agency through multiple prior delivery orders addressing sophisticated research needs, including in vitro and in vivo assays for therapeutic assessment. Beyond federal contracts, Eitr Biologics has secured grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the Office of the Director for Phase I Small Business Innovation Research (SBIR) work on bispecific nanotherapeutics and betacoronavirus medical countermeasures, demonstrating its capabilities in developing cutting-edge solutions for emerging infectious disease threats.
Quick answers
Who was awarded contract HT942524F0269?
HT942524F0269 was awarded to Eitr Biologics, Inc. by Defense Health Agency (Department of Defense) on September 20, 2024.
How much is contract HT942524F0269 worth?
The government has obligated $1,864,156 on HT942524F0269. Its potential value, with all options, is $1,864,756.
Is contract HT942524F0269 an order under another contract?
Yes. HT942524F0269 is a delivery order under HT942523D0011, an indefinite delivery contract.
Was contract HT942524F0269 competed?
The extent of competition for HT942524F0269 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award